Intellia Therapeutics (NTLA) Stock Discussions on Social Media

This commenter @Chris is looking for any excuse to bash Intellia, Editas, and Crispr, and almost anything that happens in the world @Chris negatively ties to these gene-editing stocks in an attempt to persuade investors to sell their shares. Of course, those sales would benefit @Chris and his shorting/investing friends, as they scoop up cheap(er), and short, shares. Intellia is a rocket and it's about to blast off in 2021. Will it oscillate and go and up down like every stock, sure, but on balance it's going up, up, and up. President-elect Biden just appointed Eric Lander as his top scientific adviser, and Lander is -- what else? -- a geneticist who co-led the Human Genome Project. Gene-editing is the future of medicine.

Wall st is gonna start targeting cathy wood ark positions u can guarantee a massive reversion is coming $nndm $tsla $ntla etc

Intellia Therapeutics reached an all time high at 87.04

With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting EdgeBy Bill AlpertJan. 14, 2021 3:11 pm ETOrder ReprintsPrint Article Illustration by Marcus MarrittText sizeThe Nobel Prize got Wall Street’s attention. On Oct. 7, the Swedish Academy awarded 2020’s Nobel in chemistry to two scientists for the development of Crispr-Cas9—a molecular scissors that can find and edit almost any sequence in a cell’s DNA. The 2012 discovery by Emmanuelle Charpentier and Jennifer Doudna had been commercialized with rare speed, and the Nobel was a boost for three companies founded to develop Crispr gene-editing therapies: Crispr Therapeutics, Intellia Therapeutics, and Editas Medicine. The three gene-editing stocks have more than doubled in the past few months, reaching a total market value above $23 billion.

A new variant for CRISPRIn a new study, researchers from Michigan Medicine at the University of Michigan, US, revealed that using a novel variant to repair DNA can improve both safety and effectiveness of CRISPR-Cas9 for genetic research.According to the scientists, the safety and efficacy of CRISPR-Cas9 are what continue to hold the gene editing technique back from its full clinical potential.To develop their variant, the researchers fused a minimal motif consisting of 36 amino acids to a gene-editing nuclease Streptococcus pyogenes Cas9 (spCas9). According to the team, the new meticulous integration Cas9 (miCas9) binds RAD51 through this fusion motif and enriches RAD51 at the target locus.

We would like to welcome you on board on our flight to 100B valuation, we know you had other choices and we thank you for choosing the CRISPR Sector. Flight EDIT has a technical problem with the engine and will depart as soon as there is a new CSO. Special thanks go to our investors who are collecting dollars on this flight. Thanks again and see you at the destination.$EDIT $NTLA $CRSP $BEAM

Don't go up too much NTLA, I have further acquisition in Feb. planned. I like the fact that out of my 4 genomics holdings NTLA became my largest just because it was cheapest when I bought into all of them.

$NTLA moves past $EDIT for the moment. Interesting .... any comments from the group as to why?

Nothing will be able to stand in the way of this lightning speed technology...the entire infrastructure of medicine .......insurance companies...drug companies....the methods of treatment .....will all be changing...doctors that have for decades been treating “symptoms”...with the latest “pill”...will be seeking work because the money Making machine of medicine will be forever changed.....tough times are ahead for those in the field of the money making medical machine of the past....diseases like juvenile diabetes will no longer be the lifetime sentence that it has been...and the monthly doctor visits...the daily pill...or injections required to keep people alive will forever be gone....there will always be those that try to stand in the way of change like this....but I question their motives...is it ignorance ....or greed...maybe a combination of both.

@Chris: Why get nasty and call people "morons"? Everyone is entitled to their opinions, but when they -- meaning you -- lob insults for no reason, they lose others' respect. You're shorting these gene-editing stocks, which is why you're so angry at their, now, steadfast success. To respond to your description of "overvalued": Every single biotech in the history of biotech can potentially be called "overvalued" until they produce a marketable drug, but, @Chris, they're really not, particularly when their future looks as bright as Intellia's. Kite Pharmaceuticals was sold for $11 billion dollars a few years back without one single product, or even one approval. So, @Chris, you have no idea what you're talking about, but I won't call you a "moron," as you have others, because ... well ... you've shown yourself to be one, and nasty too. This is the beginning for Intellia, which has several upcoming milestones this year, 2021, and right now its share price is a bargain. It'll probably be $150 within six months, and worth it. The only reason Intellia fell today as much as it did -- and comparatively not that much -- is because Editas' chief scientific officer announced he was leaving the company. For all we know, he was fired.

Never had so many people so concerned for my financial welfare before....lol

Red day, $NTLA holding nicely, $BEAM and $CRSP already recovering but $EDIT needs to get its 'stuff' together, pick a team and go for it.

Catherine Wood, portfolio manager for ARK thinks Gene Editing Stocks could outperform Tesla because of potential to cure diseases. Article on Guru Focus in the NEWS Section of ARKG on Yahoo Finance. WOW.....

Today, January 8, 2021: Intellia is having milestones come up within the first quarter of 2021, and all indications are they'll be positive. I would not sell my shares for anything in the world. Look at CRSP, which is now $190 a share and was $210 earlier today -- I'm betting Intellia will follow suit and match CRSP's share price; additionally, today, Raymond James increased Intellia's price target to $106. Traders and shorts want to encourage people to sell their Intellia shares because it suits their financial purposes.

Now is the perfect time to get in if you were hesitating.

$CRSP and the other genomic plays ($EDIT $NTLA $NVTA $PACB) are the kind of stocks that you shouldn't be buying based purely on valuation. you either believe in the potential or you dont. for those of us that believe, I think we will rewarded 10x over. IMO

This has been a good day. Which was..... unexpected

I wanted to but stocks since a while missed out so far, do you think it’s a good time to buy at market opening or are we expecting a dip?

$EDIT $NTLA $CRSP the SP and Chart movements of these 3 companies are rising and falling in unison this week and today is no different. I’d say it’s the CRISPR space being valued more than the individual companies.

I got in at $13 so needless to say its been a great transaction. I still think there is more gain to have once they get further along. I am am not selling...yet..